Introduction: Clinical manifestations of the hypothalamic hamartoma-epilepsy syndrome (HH-ES) in adulthood are variable. Efficacy of therapeutic options and outcome are diverse. Methods: Retrospective study of adult patients diagnosed with a HH in magnetic resonance imaging and epilepsy who attended our tertiary Epilepsy Unit between 2003 and 2018. We report the clinical and electroencephalographic features of a series of adult patients with HH and related epilepsy seen in our center together with the treatments and seizure outcome. Results: We describe a series of eight patients. Five males (62.5%), median age at evaluation was 28.5 years (IQR: 15.5). Clinical manifestations included focal with preserved and impaired awareness emotional seizures (gelastic seizures [GS]) in six patients (75%), focal tonic, atonic with impaired awareness and focal to bilateral tonic-clonic seizures. Mild GS were the only symptom in one patient. Three patients (37.5%) had endocrinological disturbances such as obesity and hypothyroidism. Fifty percent of the patients showed psychiatric comorbidity such as anxiety disorder and aggressiveness, and two patients had psychomotor delay. Seven patients (87.7%) had drug-resistant seizures and three of them were treated with radiosurgery. Out of the treated group, only one (33.3%) became seizure-free 2 years after surgery but developed psychiatric problems. The other two patients had an Engel IV outcome and received a vagal nerve stimulation (VNS) implant. VNS did not lead to changes either in intensity nor in seizure frequency. Conclusions: Hypothalamic hamartoma-epilepsy syndrome clinical manifestations in adult patients are as variable as at pediatric age. Outcome of therapeutic options such as radiosurgery or VNS may be poorer at this stage. K E Y W O R D S adult, epilepsy, hypothalamic hamartoma, radiosurgery, seizures, treatment, vagus nerve stimulation
| INTRODUC TI ON
Hypothalamic hamartomas (HH) are composed of ectopic neural and glial tissue and represent a notable etiology of treatment-resistant epilepsy. Two different clinical phenotypes are described depending on the location of the hamartoma. Those HH that invade mainly the anterior hypothalamus may develop endocrinological disturbances such as central precocious puberty (CPP) and those HH affecting the posterior hypothalamus and the mammillary bodies associate drug-resistant seizures that usually start in the early childhood as gelastic seizures (GS) (Harrison, Oatman, & Kerrigan, 2017; Kerrigan et al., 2017) .However, HH have a wide clinical expression spectrum (Mullatti et al., 2003; Striano & Striano, 2017 ) that ranges from a few seizures with normal cognitive development to a catastrophic epileptic encephalopathy (EE) resembling a Lennox-Gastaut-like syndrome with cognitive impairment and severe behavioral disturbances (Cross & Spoudeas, 2017; Scheffer et al., 2016) . We present the clinical features, electroencephalographic (EEG) recordings, imaging findings, and therapeutic options in a series of adult patients with epilepsy due to hypothalamic hamartoma.
| MATERIAL AND ME THODS
We reviewed all patients with epilepsy and HH referred to the Epilepsy Unit of Hospital Clínic (Barcelona, Spain) between 2003 and 2018. We included those patients with history of seizure and magnetic resonance imaging (MRI) evidence of an HH defined by a T2-weighted image hyperintense and T1-weighted image hypointense lesion, that involves the hypothalamus, mammillary regions, tuber cinereum, and/or third ventricle floor. Patients with dual pathology were also included.
Evaluation included a detailed clinical history and examination.
We analyzed treatment choices, age at evaluation and seizure onset, sex, type of seizures according to the International League Against Epilepsy (ILAE) classification (Delalande & Fohlen, 2003) , frequency of seizures, scalp EEG or video-EEG recordings, MRI findings according to the Delalande and Fohlen classification (Palmini, Paglioli-Neto, Montes, & Farmer, 2003) , endocrine disturbances, psychiatric comorbidities, cognitive status, current antiepileptic drug (AED) therapy, and nonpharmacological treatment of the HH. We report single photon emission computed tomography (SPECT) and subtraction ictal SPECT coregistered to MRI (SISCOM) results, when obtained during admission in patients who went through presurgical evaluation. Nonpharmacological treatment is discussed. The study was approved by the Healthcare Ethics Committee of the Hospital Clínic de Barcelona.
| RE SULTS

| Demographic and epilepsy history data
Eight patients fulfilled the inclusion criteria, five were males (62.5%), median age at evaluation was 28.5 years (IQR: 15.5) and median age at seizure onset is 2 (range 0.2-13) years of age. Patients had no other risk factors for epilepsy.
Six patients (75%) had focal aware emotive (gelastic) seizures as initial symptom. GS were the only seizure type in one patient who often experienced repetitive gelastic status epilepticus. In the remaining five cases, GS coexisted with other seizure types. One patient (No. 4) referred a mirth sensation or "need of laugh" instead of frank bursts of laugh. Four out of eight (50%) had focal seizures with impaired awareness, three out of eight (37.5%) had focal to bilateral tonic-clonic seizures and one had psychogenic nonepileptic seizures (PNES) in addition to GS. Two patients (No. 3 and No. 8 
| Neuroimaging
| MRI
All patients had lesions compatible with HH in 1.5 and 3 Tesla Brain 
| Functional neuroimaging studies
| EEG data
Electroencephalographic findings in our group are summarized in consists of an abrupt background diffuse attenuation followed by a brief burst of fast generalized polyspikes and then bursts of generalized rhythmic fast activity lasting a few seconds, at a variable frequency between 14 and 24 Hz, which then evolved into slow spike-wave activity. This pattern was the most consistent one through the sample.
| Outcome and comorbidities
None of our patients have had signs of CPP; two had hypothyroidism and were on hormonal therapy; one had obesity and dyslipidemia. Six patients (75%) had a normal neurodevelopment, one had anxiety, and another had an isolated episode of psychosis which was attributed to antiepileptic therapy. The remaining two patients (25%) had severe cognitive impairment: one of them developed a severe encephalopathy with language disturbance, aggressiveness and a compulsive eating disorder; the other patient also had severe behavioral alterations with aggressiveness and a severe verbal memory loss corroborated by neuropsychological studies. Both patients began with GS before 1 year of age.
| Treatment
Median number of AEDs per patient was three drugs (range 0-4).
Two patients took <3 AEDs: one of them had mild occasional GS and decided to stop medication on his own; the other patient was controlled with one drug ( The other patients showed no changes in seizure frequency after the procedure. The patient who achieved an Engel Ib outcome received radiosurgery at an older age compared with the other two patients. Median epilepsy duration at radiosurgery was 14.83 years (range 5.5-25 years), but age at onset did not seem to be a determinant factor contributing to outcome in our series.
Two out of the three patients treated with radiosurgery and poor outcome underwent vagus nerve stimulation (VNS) implantation. In the first case, it had to be switched off because of lack of efficacy and respiratory side effects (apneas and hypopneas). In the second case, the effect of the device was quite modest and did not achieve seizure control. Initially output current parameters oscillated from 1 to 2.5 mA, signal frequency 30 Hz, signal pulse width 500 us, and "on" and "off" time: 30 s on and 5 min off.
| D ISCUSS I ON
Our series is a good example of the variable clinical expression of HH in the adult age and its low prevalence. HH is a rare condition, with an estimated prevalence of 1-2 cases per 100,000 population (Striano et al., 2012) . We practice at a referral center in Spain for drug-resistant epilepsy, and we identified eight patients in our database. We could not find any patients with frank GS in the context of frontal or temporal lobe epilepsy, without associated HH. HH is usually sporadic, but in 5% of cases can be associated with the Pallister-Hall syndrome (Georgakoulias, Vize, Jenkins, & Singounas, 1998; Scheffer et al., 2016) . The initial presentation in the sporadic cases usually occurs in the first months of life as GS. In 50% of the cases, it may progress to a disabling epileptic syndrome with multiple types of seizures typically refractory to antiepileptic therapy resembling a severe encephalopathy with possible additional features such as endocrinological and psychiatric disturbances Ng et al., 2006; Oehl et al., 2010; Striano et al., 2012) .
Our series also illustrates that diagnosis may be challenging spe- and often smaller lesions that did not protrude into the lumen of the third ventricle (Striano, Striano, Sarappa, & Boccella, 2005 There is not a definitive predictor of evolution patterns and clinical variability in HH patients but it is known that clinical expression and syndrome severity are related to the dimension, location, and attachment of the HH (Georgakoulias et al., 1998) . Often the sessile masses associate epilepsy and the pedunculated ones may be related to endocrinological disturbances and/or to visual impairment (Kameyama, Masuda, & Murakami, 2010) . Some authors suggest that larger hamartomas are frequently associated with higher seizure severity, cognitive impairment, and behavioral disorder as signs of EE probably due to hypothalamic-thalamic-mammillary connections dysfunction (Deonna & Ziegler, 2000; Frattali et al., 2001; Prigatano, 2007; Tezer, Pektezel, Gocmen, & Saygi, 2014) . In our experience, the most severe cases with pronounced cognitive decline were the ones that started earlier with GS, suggesting that age of onset may also play a predictor role in HH-ES outcome. Severity may be also related to duration of epilepsy, the cases who started earlier and did not achieve seizure freedom may progress to an EE. However, patient No. 5 presented a giant hamartoma and early onset of GS but showed no developmental delay, behavioral or psychiatric problems.
This raises the question of whether location and invasion of close
structures may be the most important factors related to epilepsy severity.
The hamartoma location influences the regulation of hormone release. Pedunculated HH occupying the anterior hypothalamus (Type I) may cause endocrinological disturbances, being the CPP the most frequent one, probably because of a premature pulsatile release of gonadotropin-releasing hormone (GnRH) from the hypothalamus (Harrison et al., 2017; Striano & Striano, 2017) . CPP and epilepsy coexist in up to 45% of the patients undergoing surgical treatment for epilepsy (Oehl et al., 2010) . Other disturbances include secondary or tertiary hypothyroidism and weight gain with obesity.
Infrequent comorbidities are Addisonian crisis and central diabetes.
Sleep disturbances like hypersomnia (Dunn, Deroo, & Rivara, 2001) and reduction in REM sleep have been described and may worsen seizure severity (Cross & Spoudeas, 2017; Troester et al., 2011) .
None of the patients in our series had history of CPP, even when masses were large enough to invade the anterior hypothalamus. Two patients presented hypothyroidism and another one severe central obesity and dyslipidemia. epileptiform features demonstrating generalized, multifocal, and/or focal discharges and suggesting that EEG is not a specific test for the diagnosis of HH-epilepsy disorders (Scholly et al., 2013) . Ictal recordings may be variable too, though GS show no obvious ictal changes in the majority of events (Gutierrez et al., 2016) , non-GS may show epileptic activity mainly in frontal and temporal lobes (García-Morales et al., 2007; Scholly et al., 2013) .
This lack of electric correlate, especially in patients with subtle GS, makes the diagnosis of HH-ES challenging in patients with less severe seizures. Scholly et al. introduced the concept of "hypothalamic plus" epilepsy, as a result of secondary epileptogenesis mechanisms referring to the functional involvement of the frontal and temporal lobes in the HH epileptogenic network (Kerrigan, Ng, Chung, & Rekate, 2005; Régis et al., 2017; Striano & Striano, 2017) .
In our study, one patient showed unilateral HS and another patient had bilateral HS. This findings may relate to potential secondary epileptogenesis which is probably linked to the anatomic and functional connectivity of the hypothalamus with frontal lobes, limbic system, and thalamus (Wu, Gao, Shen, Qiu, & Kerrigan, 2015) . HH has been demonstrated to be an intrinsically epileptogenic lesion from stereoelectroencephalography recordings within the lesion (Kahane, Ryvlin, Hoffmann, Minotti, & Benabid, 2003; Munari et al., 1995) . Kahane et al. proposed a pathway based on the HH strong connectivity to mammillo-thalamo-cingulate tract that could spread epileptic activity to the cingulate and from here to temporal or frontal areas. A secondary "kindling"-like effect of the primary HH could explain why these interconnected brain areas develop the ability to independently generate seizures (Harvey & Freeman, 2007; Kahane et al., 2003) .
Cellular mechanisms responsible for epileptogenesis are unknown but the intrinsic epileptogenicity of HH was explained by the microanatomic organization and electrophysiologic characteristics of HH neurons. The predominant type of neurons are small HH neurons (SHH), they account for approximately 90% of the cells and they have a tendency to cluster (Fenoglio et al., 2007) . These SHH appear to have an interneuron-like phenotype that expresses γ-aminobutyric acid (GABA) and a tendency for intrinsic pacemaker-like firing activity. There are also large HH (LHH) neurons which are functionally immature and usually at rest but with paradoxical depolarization and firing in response to GABA ligands. LHH represent around 10% of the neuron population in HH tissue and seem to have a phenotype of excitatory projection-type neuron by using excitatory glutamate as their primary neurotransmitter (Striano et al., 2002) .
Treatment should be individualized depending on the radiological characteristics of the HH, AED response and tolerability, seizure severity, and availability of surgical techniques in each center. Epilepsy associated with HH is known to be in most cases drug-resistant and there is no data whether medication makes any difference to the natural history of the condition or any longer-term benefit (Scheffer et al., 2016) . Most series however come from surgical centers and this may introduce a significant bias toward more severe cases.
Surgical treatment may have an effect on seizures and additional comorbidities producing a "running-down-like" phenomenon, stopping or even reverting the evolution of the HH-ES and should be performed as early as possible (García-Morales et al., 2007; Régis et al., 2017; Savard, Bhanji, Dubeau, Andermann, & Sadikot, 2003; Scholly et al., 2013; Striano & Striano, 2017 Only small studies of HH and VNS therapy have been published suggesting that this device could have a very modest effect on seizure control (Brandberg, Raininko, & Eeg-Olofsson, 2004; Murphy, Wheless, & Schmoll, 2000) . We implanted the VNS device in two patients with intractable epilepsy who previously failed to respond to radiosurgery. Output current parameters were modified following absence of response to different duty cycles. In our sample, there was no effect on seizure frequency or severity, and only one of them experienced behavior improvement. As it is known for other therapies, late use of drugs and devices is associated to a worse seizure outcome, due to increased drug resistance.
Hypothalamic hamartomas diagnosed in adulthood may show a poorer prognosis to surgical treatment than during childhood because comorbidity and encephalopathy tend to remain following the intervention. In our sample, out of three patients who began seizures in the first months of life, two progress to a disabling epileptic syndrome with multiple types of seizures refractory to antiepileptic therapy, resembling a severe encephalopathy, with additional cognitive and psychiatric disturbances. Lack of seizure control and impairment of mental development have a direct influence on social adaptation and usually condemn patients to depend on a caregiver.
Patients with HH-ES develop progressively behavioral deterioration and developmental delay. However, there are some patients that may present with early seizure onset but represent a mild end to the clinical spectrum as illustrated by patient No. 4. This fact reminds us that cognitive or behavioral disturbances may not always be present and leads our current of thought to the point that location and connectivity of the HH to close structures may be the most important factors related to epilepsy severity.
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